Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €96.11 EUR
Change Today -0.16 / -0.17%
Volume 22.7K
BIM On Other Exchanges
BIM is not on other exchanges.
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - €106.00
52 Week Low
09/3/14 - €76.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux S.A. provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, and software for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products. Its technologies and systems include clinical microbiology products, such as automated VITEK 2 system and Etest for the identification of bacteria and analysis of their susceptibility to antibiotics; VITEK MS, a mass spectrometry-based system for the identification of bacteria, fungi, and mycobacteria; culture media products; BacT/ALERT for the culture and detection of bacteria present in blood; Full Microbiology Lab Automation system; and molecular diagnostics products. The company also provides immunoassays products comprising VIDAS, an immunoassay system; and bioNexia and VIKIA range of products for conducting rapid tests. In addition, it offers molecular biology products, including NucliSENS easyMAG and NucliSENS miniMAG for extraction; and ARGENE and NucliSENS EasyQ for amplification and detection. Further, the company offers industrial microbiology products, such as bacteriophages and cytometry products; and TEMPO, an automated microbiological testing system for food-processing applications. Additionally, the company provides Myla, an information technology solution for microbiology laboratories; PREVI Isola, an automated inoculation system for culture media; and PREVI color gram for the automated gram staining of sample slides containing microorganisms. The company, formerly known as B-D Mérieux, was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,062 Employees
Last Reported Date: 04/28/15
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €669.5K
Compensation as of Fiscal Year 2014.

biomerieux (BIM) Key Developments

bioMérieux Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

bioMérieux reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported consolidated sales amounted to €448 million in the first quarter of 2015, up from €371 million in the year-earlier period. Organic growth came to 8.7%, marking a clear acceleration compared with first-quarter 2014. On a reported basis, sales ended the period up 20.8% year-on-year, lifted by the €37 million positive currency effect and the two additional weeks of sales from BioFire, which was acquired and consolidated as of January 16, 2014. At March 31, 2015, after payment of taxes and variable compensation, net debt stood at €283 million.

bioMérieux SA to Recommend Dividend for the Year 2014, Payable on June 9, 2015; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Capital Expenditure Guidance for the Year of 2015

The board of directors of bioMérieux SA will recommend that shareholders at the Annual Meeting on May 28, 2015 approve a dividend of EUR 1 per share, unchanged from the dividend paid in 2014. This would represent a total payout of EUR 39.5 million, to be paid on June 9, 2015. The company reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported sales of EUR 1,698.4 million compared to EUR 1,587.9 million a year ago. Operating income before non-recurring items was EUR 202.9 million compared to EUR 260.5 million a year ago. Operating income was EUR 203.6 million compared to EUR 257.5 million a year ago. Net income of consolidated companies was EUR 135.5 million or EUR 3.42 per basic and diluted share compared to EUR 164.7 million or EUR 4.16 per basic and diluted share a year ago. EBITDA was EUR 332.2 million compared to EUR 353.3 million a year ago. Net cash flow from operations was EUR 298.3 million compared to EUR 240.5 million a year ago. Purchase of property, plant and equipment was EUR 158.1 million compared to EUR 131.1 million a year ago. Free cash flow was EUR 158 million compared to EUR 111 million a year ago. Net debt amounted to EUR 249 million at December 31, 2014, compared with EUR 25 million in net cash a year earlier. The company expects to drive sales growth of between 3% and 5% in 2014, at constant exchange rates and scope of consolidation. The company expected to generate around EUR 60 million in sales in 2014, while its contribution to the growth in consolidated sales will be reported in "changes in the scope of consolidation" for the year. Contributive operating income before non-recurring items of between EUR 220 million and EUR 245 million, after recognition of company’s recurring operations, the investments required at the Durham site and the currency effect (at least an estimated EUR 25 million on the basis of current exchange rates). The company has set an organic growth objective of between 4.5% and 6.5% for the year, at constant exchange rates and scope of consolidation. The company is aiming to increase contributive operating income before non-recurring items to between EUR 240 million and EUR 265 million in 2015, at current exchange rates. This objective reflects the selling costs that will be invested to ensure FilmArray®'s success and the operating expenses that will be incurred to strengthen the operating organization in the Asia-Pacific and to anchor the company's sustained development in the region. This objective also includes the priority projects that will be led by the company in 2015 to enhance its operating performance, in particular by revamping the supply chain and improving customer service, deploying new sales performance management applications and optimizing the management of R&D programs. In addition, using its structural capacity for strong cash generation, the company will increase its industrial capital expenditure potentially to around EUR 200 million.

bioMérieux SA Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015

bioMérieux SA Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015 . Venue: HSBC France Offices, 109 Avenue des Champs-Elysees, Paris, France. Speakers: Isabelle Tongio, Head of IR.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €96.11 EUR -0.16

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $53.97 USD +0.23
Bio-Rad Laboratories Inc $146.37 USD -3.58
Bruker Corp $20.37 USD -0.19
Cepheid $58.04 USD -3.09
QIAGEN NV €22.30 EUR -0.045
View Industry Companies

Industry Analysis


Industry Average

Valuation BIM Industry Range
Price/Earnings 25.8x
Price/Sales 2.0x
Price/Book 2.5x
Price/Cash Flow 25.8x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at